ZA200400917B - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor. - Google Patents
Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor. Download PDFInfo
- Publication number
- ZA200400917B ZA200400917B ZA200400917A ZA200400917A ZA200400917B ZA 200400917 B ZA200400917 B ZA 200400917B ZA 200400917 A ZA200400917 A ZA 200400917A ZA 200400917 A ZA200400917 A ZA 200400917A ZA 200400917 B ZA200400917 B ZA 200400917B
- Authority
- ZA
- South Africa
- Prior art keywords
- glycyl
- pharmaceutical composition
- glycine
- polysaccharide
- group
- Prior art date
Links
- 229920001282 polysaccharide Polymers 0.000 title claims description 58
- 239000005017 polysaccharide Substances 0.000 title claims description 58
- 206010027476 Metastases Diseases 0.000 title claims description 37
- 230000009401 metastasis Effects 0.000 title claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 31
- 201000011510 cancer Diseases 0.000 title claims description 20
- 230000002401 inhibitory effect Effects 0.000 title claims description 11
- 150000004676 glycans Chemical class 0.000 title claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 29
- 150000005846 sugar alcohols Polymers 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 239000013543 active substance Substances 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 230000000259 anti-tumor effect Effects 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- -1 glycyl-glycyl- glycyl-glycyl Chemical group 0.000 claims description 11
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 9
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- GLUBLISJVJFHQS-SECBINFHSA-N 2-[[(2r)-2-azaniumyl-3-phenylpropanoyl]amino]acetate Chemical compound OC(=O)CNC(=O)[C@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-SECBINFHSA-N 0.000 claims description 6
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 6
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 229940127093 camptothecin Drugs 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 claims description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 108010008488 Glycylglycine Proteins 0.000 claims description 3
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 claims description 3
- 229940043257 glycylglycine Drugs 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- HPYDSVWYXXKHRD-SECBINFHSA-N 2-[[(2r)-2-azaniumyl-3-(4-hydroxyphenyl)propanoyl]amino]acetate Chemical compound OC(=O)CNC(=O)[C@H](N)CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-SECBINFHSA-N 0.000 claims description 2
- LESXFEZIFXFIQR-ZCFIWIBFSA-N D-Leu-Gly Chemical compound CC(C)C[C@@H]([NH3+])C(=O)NCC([O-])=O LESXFEZIFXFIQR-ZCFIWIBFSA-N 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 150000004804 polysaccharides Chemical class 0.000 description 49
- 239000000203 mixture Substances 0.000 description 36
- 238000003756 stirring Methods 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 229920002307 Dextran Polymers 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 12
- 238000002513 implantation Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- YJVXEQJVAOGXKM-UHFFFAOYSA-N 2-ethoxy-2h-quinoline-1-carboxylic acid Chemical compound C1=CC=C2N(C(O)=O)C(OCC)C=CC2=C1 YJVXEQJVAOGXKM-UHFFFAOYSA-N 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 210000000742 appendix Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000315 cryotherapy Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- 238000000015 thermotherapy Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- HXUVTXPOZRFMOY-NSHDSACASA-N 2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 HXUVTXPOZRFMOY-NSHDSACASA-N 0.000 description 1
- GHONIQQBOSTHSL-UHFFFAOYSA-N 2-[[2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]acetyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(=O)NCC(=O)NCC(O)=O GHONIQQBOSTHSL-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 101100020289 Xenopus laevis koza gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000011932 ovarian sarcoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 238000011250 post-surgery chemotherapy Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
A
PHARMACEUTICAL COMPOSITIONS COMPRISING POLYSACCHARIDE CONJUGATES FOR
INHIBITING THE METASTASIS OR PREVENTING THE RECURRENCE OF MALIGNANT TUMOR
LC)
The present invention relates to a pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor. More particularly, the present invention relates to a pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity, for example, a camptothecin derivative of the formula (I) or (II) as mentioned below, via an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different, or a salt thereof.
Malignant tumors are one of the main causes of death in the developed countries, and the majority of malignant tumors related deaths are due to metastasis into distant organs or recurrence accompanied by metastasis to distant
'
X organs after a topical therapy. The metastasis to distant organs may be caused by hematogenous metastasis or lymphogenous metastasis, and it is known that a patient having lymphogenous metastasis has a high risk of
S recurrence of a malignant tumor after topical therapy. The main organs of recurrence are brain, lung, liver, and bone.
Especially, a tumor in digestive apparatus, for example, colon cancer from which a large number of patients are suffered, may often invade and spread to the liver, and a breast cancer and a lung cancer as well often invade and spread to the liver. Further, a lymphoma and a lymphatic leukemia may spread mainly to the lymph system, and it has been reported that the metastasis to liver was observed in high rate by autopsy.
In order to inhibit the recurrence including the metastasis to distant organs such a metastasis to the liver and to prolong life, a chemotherapy, etc. is employed as a supportive care after a topical therapy, but the chemotherapy has a potent toxicity and cannot be used for chronic administration. In addition, it has scarcely been reported that the lifetime is more prolonged by a supportive care of chemotherapy than a topical therapy alone. For example, in the trials of post-surgery chemotherapy for the patient who is the subject of surgery of advanced gastric cancer, one of the cancers of digestive i. organs, clinical tests of various agents for anti-malignant tumors have been tried, but any therapeutic method exhibiting a remarkably better survival rate than a surgery alone has not been established yet.
Under these circumstances, it has been desired to find a new agent effective in inhibiting recurrence or in prolonging life after topical therapy, which is applicable to the lymph node and the distant organs of metastasis with little side effects, and is suitable for chronic administration.
On the other hand, WO 94/19376, WO 97/46260, WO 97/38727, JP-A-10-72467 and JP-A-10-95802 disclose a polysaccharide derivative comprising a polysaccharide bound to an active substance having an anti-tumor activity via an amino acid or a peptide.
However, these publications disclose the use of these polysaccharides in the treatment of cancers by accumulating at the tumor site and killing the tumor cells, but never indicate activities of inhibiting metastasis or preventing recurrence of a malignant tumor.
An object of the present invention is to provide a novel pharmaceutical composition for inhibiting the metastasis or preventing the recurrences of a malignant tumor. .
The present inventors have intensively studied, and have found that a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide exhibits an excellent effect in the inhibition of metastasis and/or prevention of recurrence of a malignant tumor, and have accomplished the present invention. That is, the present invention relates to pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different, or a salt thereof.
Fig 1 shows the lapsed days after implantation of tumor and the number of survived animals in M 5076 liver metastatic models.
The polysaccharide having a carboxyl group of the
’ present invention includes the same ones as those disclosed . in the above mentioned WO 94/19376 and WO 97/46260, and includes polysaccharide having originally carboxyl groups in the structure thereof (e.g., hyaluronic acid, pectic acid, alginic acid, chondroitin, heparin, etc.), and polysaccharides having originally no carboxyl group (e.g., pullulan, dextran, mannan, chitin, mannoglucan, chitosan, etc.) but being introduced thereto carboxyl groups, and polysaccharides having originally no carboxyl group in the structure thereof but being introduced thereto carboxyl groups after polyalcohol formation (e.g., polysaccharide polyalcohol having a carboxyl group).
The polysaccharide having originally no carboxyl group but being introduced thereto a carboxyl group means ones that are prepared by substituting a hydrogen atom of a part or all of hydroxyl groups of polysaccharides having originally no carboxyl group with a carboxy-C,, alkyl group.
In the present invention, the polysaccharide having a polysaccharide includes one that are prepared by treating a polysaccharide originally having no carboxyl group with a reducing agent, and then followed by substituting a hydrogen atom of a part or all of hydroxyl groups of the resultant with a carboxy-C,., alkyl group.
The polysaccharide polyalcohol having a carboxyl group includes, for example, a carboxy-C,, alkyl-polysaccharide polyalcohol which is prepared by treating a polysaccharide originally having no carboxyl group successively with sodium periodate and sodium borohydride by the method . disclosed in WO 97/46260 to give a polysaccharide polyalcohol, which is further treated with a halogenated
C,., alkylcarboxylic acid.
The alkyl moiety of the carboxyl-C,, alkyl group which substitutes a hydrogen atom of the hydroxyl groups of the above polysaccharide (including a polysaccharide polyalcohol) may be either a straight chain alkyl group or a branched chain alkyl group.
Preferable carboxy-C,, alkyl group is, for example, carboxymethyl group, l-carboxyethyl group, 3-carboxypropyl group, l-methyl-3-carboxypropyl group, 2-methyl-3-carboxy- propyl group, 4-carboxybutyl group, etc., and carboxymethyl group is more preferable.
In the present invention, the polysaccharide having a carboxyl group is preferably carboxy-C,, alkyldextran or carboxy-C,., alkyldextran polyalcohol, and carboxyl-C,_, alkyldextran is especially preferable.
The degree of polyalcohol formation (by the successive oxidation with sodium periodate and reduction with sodium borohydride) in the step of preparing the carboxy-C,_, alkyl-polysaccharide polyalcohol as mentioned above is not specified, but the intermediate polysaccharide pclyalcohol is preferably one being obtained by treating a polysaccharide under possible conditions for substantially almost completely forming polyalcohol.
Moreover, in the present invention, the polysaccharide having a carboxyl group is preferably carboxymethylated dextran or carboxymethylated dextran polyalcohol, and among these polysaccharides, particularly dextran having an average molecular weight of 20,000 to 500,000 is more preferable, and dextran having an average molecular weight of 50,000 to 350,000 is most preferable (said average molecular weight being determined by Gel permeation chromatography (GPC) method, Shinseikagaku, Jikken Koza, vol. 20, p. 7, Tokyo-Kagaku-Dojin, November 5, 1991).
When introducing a carboxylalkyl group into polysaccharides, the degree of the introduction thereof is expressed by "degree of substitution” which is defined by a number of carboxylalkyl groups (including groups of peptide chain being introduced by these groups) per a sugar residue.
That is expressed by the following equation.
Number of carboxyalkyl groups
Degree of — in the molecule
Substitution Total number of sugar residues in the molecule
When the carboxylalkyl group is carboxymethyl group, : the degree of substitution is occasionally expressed by the degree of carboxymethylation (CM-degree).
When the polysaccharide is dextran, the degree of substitution thereof is preferably in the range of 0.3 to 0.8. When the polysaccharide is dextran polyalcohol, the degree of substitution is preferably in the range of 0.3 to 0.5.
The amino acid or peptide of the present invention plays a role of spacer existing between a polysaccharide having a carboxyl group and an active substance having an anti-tumor activity, and the amino acid or amino acid forming said peptide includes both natural amino acids and synthetic amino acid (including D-amino acids, L-amino acids, a mixture thereof), and also includes either neutral amino acids, basic amino acids or acidic amino acids.
Moreover, the amino acid of the present invention may be not only a-amino acid but also B-amino acids, y-amino acids, g—amino acids, etc.
Examples of the amino acids are glycine, a-alanine, B- alanine, valine, leucine, isoleucine, serine, threonine, systeine, methionine, aspartic acid, glutamic acid, lysine, citrulline, arginine, phenylalanine, tyrosine, histidine, tryptophan, proline, hydroxyproline, y-aminobutyric acid, ge~-aminocaproic acid, etc.
The peptide of the present invention includes ones consisting of 2 to 8 amino acids, preferably 2 to 5 amino acids, which are the same or different. Examples of the peptides are glycyl-glycyl-L- or D-phenylalanyl-glycine, ’ glycyl-glycine, glycyl-glycyl-glycine, glycyl-glycyl- glycyl-glycine, glycyl-glycyl-glycyl-glycyl-glycine, L- or
D-phenylalanyl-glycine, L- or D-tyrosyl-glycine, L- or D- leucyl-glycine, L- or D-phenylalanyl-citrulline and L- or
D-valyl-citrullin (the N-terminus of these peptides is introduced onto the carboxyl group of a polysaccharide).
Among these peptides, glycyl-glycyl-L- or D-phenyl- alanyl-glycine, glycyl-glycine, glycyl-glycyl-glycine, glycyl-glycyl-glycyl-glycine, glycyl-glycyl-glycyl-glycyl- glycine, and L- or D-phenylalanyl-glycine are preferable.
The active substance having an anti-tumor activity of the present invention may include various compounds being known as an anti-tumor agent, and may be either cytotoxic agents or cytostatic agents. The cytotoxic agent is preferably camptothecin derivatives and taxane derivatives, and the cytostatic agent is preferably angiogenesis inhibitors, EGF receptor inhibitors. More preferably, the cytotoxic agent is camptothecin derivatives, and the cytostatic agent is angiogenesis inhibitors.
Examples of camptothecin derivatives are compounds disclosed in JP-A-10-72467 of the formula (I):
. \ a
R' o) “dl ~ N e) one LIS (1)
N R @)
HsCY “oH wherein R' is a substituted or unsubstituted lower alkyl group, X' is a group of the formula: -NHR? (R’ is a hydrogen atom or a lower alkyl group) and Alk is a straight chain or branched chain C,; alkylene group having optionally an oxygen atom in the chain thereof. Among them, preferable compound is 10-(3'-aminopropyloxy)-7~ethyl-(20S)- camptothecin.
Other examples of camptothecin derivatives are compounds disclosed in JP-A-~-10-95802 of the formula (II):
RS R? 0
RE Xr ON 0 0)
RES=4SY
R HCY “OH wherein two groups of R’ to R® being adjacent each other combine to form a lower alkylene group, and one of the carbon atoms of said lower alkylene group is substituted by an amino group, and the remaining three groups of R? to R® are a hydrogen atom, a lower alkyl group or a halogen atom.
Among them, preferable compound is (1S, 9S)-~-l-amino-9- ethyl-5-fluoro-2, 3-dihydro-9-hydroxy-4-methyl-1H, 12H- benzo([de]pyrano(3’,4’ :6,7]indolizino(l,2-blgquinoline-
AMENDED SHEET
10,13(9H, 15H) -dione, etc. R
Examples of taxane derivatives are Taxol, Taxotere, 13-[(2'R,3'R)-3'N-t-butyloxycarbonyl-3'-cyclopropyl]-10- deacetyl-baccatin III, etc.
In the active ingredient of the present invention, the ratio of the polysaccharide and the active substance having an anti-tumor activity may be selected according to the kinds of the polysaccharide to be used, but when the polysaccharide is dextran or dextran polyalcohol, then the content of the active substance having an anti-tumor activity is preferable in the range of 0.1 toc 20 % by weight, more preferably in the range of 2 to 10 % by weight, based on the whole weight of the active ingredient.
Among the active ingredients of the present invention, preferable ones are polysaccharide derivatives or a salt thereof wherein an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different are introduced into a part or all of the carboxyl groups of the polysaccharide having a carboxyl group through an acid- amide bond, and the remaining part or all of the amino groups or carboxyl groups which do not participate in the binding to the carboxyl groups of the above peptide are bound to the carboxyl groups, amino groups or hydroxyl groups of the active substance having an anti-tumor activity through an acid-amide bond or ester bond.
{ ©
Especially preferable active ingredient is a polysaccharide derivative, wherein the polysaccharide having an carboxyl group 1s carboxymethylated dextran, the active substance having an anti-tumor activity is 10-(3'- aminopropyloxy)-7-ethyl~ (20S) -camptothecin, and the peptide is glycyl-glycyl-glycine, or a salt thereof. Especially preferable one is a polysaccharide derivative wherein the polysaccharide having a carboxyl group is carboxymethylated dextran having an average molecular weight of 60,000 to 200,000, and the degree of carboxymethylation thereof is in the range of 0.3 to 0.8, or a salt thereof.
Other preferable active ingredient is a polysaccharide derivative wherein the polysaccharide having a carboxyl group is a carboxy-C,., alkyldextran polyalcohol, the active substance having an anti-tumor activity is (1S, 9S)-1- amino-9-ethyl-5-fluoro-2, 3-dihydro-9-hydroxy-4-methyl- 1H, 12H-benzo[de]pyrano{3’,4’:6,7]indolizino (1, 2-b]- quinoline-10,13 (9H, 15H) -dione, and the peptide is glycyl- glycyl-L- or D-phenylalanyl-glycine, or a salt thereof, and especially preferable ones are a polysaccharide derivative or a salt thereof wherein the polysaccharide having a carboxyl group is carboxy-C,, alkyldextran polyalcchol having an average molecular weight of 200,000 to 400,000, and the degree of the substitution thereof is in the range of 0.3 to 0.5.
AMENDED SHEET
The polysaccharide derivative or a salt thereof of the. active ingredient of the present invention may be prepared according to the methods disclosed in WO 94/19376, WO 97/46260, WO 97/38727, JP-A-10-72467, and JP-A-10-95802.
The pharmaceutical composition of the present "invention may highly accumulate at the site such as lymph node or the liver to which cancers may spread, can release an active substance at an appropriate rate so that the active substance hardly affects on the normal cells and suppressively acts on the growth of tumor cells, and hence, the pharmaceutical composition of the present invention is useful in the inhibition of metastasis or prevention of reoccurrence of a malignant tumor. Especially, the pharmaceutical composition of the present invention is useful in the inhibition of lymph node metastasis or liver metastasis, particularly useful in the inhibition of lymph node metastasis. Further, among lymph node metastasis, the present pharmaceutical composition is useful in the inhibition of metastasis in lymph node from the colon, or metastasis in lymph node from the lung.
In addition, the present pharmaceutical composition may exhibit its effects not only before the onset of metastasis but also after the onset of metastasis.
Therefore, the present pharmaceutical composition is also useful in the inhibition of metastasis or prevention of recccurrence of a malignant tumor after a topical therapy (e.g., surgery, radiation therapy, thermotherapy, cryotherapy, laser burning therapy, etc.). Moreover, the present pharmaceutical composition is also suitable for repetitive dosing for long time, and can be employed together with a topical therapy.
The present pharmaceutical composition is preferably administered parenterally (e.g., intravenous injection), and is usually administered in the form of a liquid preparation such as solution, suspension, emulsion, etc.
The present pharmaceutical composition is preferably formulated in the form of an injection or drip infusion by using distilled water for injection, physiological saline solution, aqueous glucose solution.
The dosage of the present pharmaceutical composition may vary according to the administration methods, age, weight or conditions of the patients, etc., but it is usually in the range of 0.002 to 50 mg/kg, more preferably in the range of 0.01 to 5 mg/kg, in single dose, converted into an amount of the active substance. :
In the present specification, the lower alkyl group and the lower alkylene group may be ones having 1 to 6 carbon atoms, preferably ones having 1 to 4 carbon atoms, and the halogen atom is fluorine atom, chlorine atom, bromine atom, iodine atom, etc.
EXPERIMENTS
Experiment 1 (M 5076 liver metastatic models)
One million of M 5076 cells (mouse ovarian sarcoma cells) were implanted into BDFl1 male mice (5-weeks old, 8 animals per group) at the tail vein. A test compound (Compound A; the compound obtained in Preparation 1 as described below and Irinotecan (CPT-11)) was dissolved in a physiological saline solution, and each amount as indicated in Table 1 as mentioned below was administered intravenously to the mice on the 4th, 8th and 12th day after the implantation, and the mice were observed for 120 days after the implantation of tumor. In the control group (untreated with test compound), only a physiological saline solution was administered. The survival time (days) was measured in both the test compound-treated groups and the control group, and the prolongation rate of survival was calculated according to the following equation. The results are shown in Table 1 and Fig. 1.
Survival days in the test
Prolongation rate __ conpound-treated group 0 of survival - 17X10
Survival days in the control group
Table 1
J ——
Prolon-
Dose Survival Standard gation (mg/kg) days error rate of survival (%)
Control 15.00 1.24 -
Compound A 12.5 37.57 5.27 150.5 25 43.13 5.98 187.5 50 48.71 5.33 224.8
Irinotecan 80 22.50 0.5 50.0 ee
As is shown in Table 1, the compound obtained in
Preparation 1 as mentioned below (Compound A) exhibited an excellent activity of prolonging lifetime in M5076 liver metastatic models. Meanwhile, Irinotecan is not known as an agent for inhibiting the metastasis or preventing the reoccurrence of a malignant tumor, but it was merely tested as a drug of camptothecin derivatives.
Experiment 2 (HT-29 metastatic models)
A segment (2 mm?) of HT-29 cells (human colon cancer) was implanted into the vermiform appendix of 100NCr nu/nu female mice (5 to 6 weeks old, 10 animals per group). A test compound (Compound A; the compound obtained in
Preparation 1 as mentioned below, Compound B; the compound obtained in Preparation 4 as mentioned below, and
Irinotechan (CPT-11)) was dissolved in a physiological saline solution, and each amount 25 indicated in Table 2 as mentioned below was administered intravenously to the mice on the 15th, 19th, 23rd and 25th day after the implantation of tumor.
On the other hand, in the control group (untreated with test compound), only a physiological saline solution was administered.
The presence or absence of the metastasis of each organ was checked on the 84th day after the implantation of tumor.
The results are shown in the following Table 2.
Sw — — oO — [es] ¥ o o o ™ o page ¥ . . . . . «” a < | + I z= nl o o — o o o o — = > 940 o D © © o Qo gE Q LI —H © o oN feo} Xs} o Xe} ~ on on o
Ze Eg 0 <r = © os 1 O ot xs [x A ¥ o o o o o o o o > 5 = x x . . . . . . . . | Q oon
Ox 0, — i — — — — — — — on
On 0 0 ~
Pall= v ono 58 E52 ox x 0 0 Hm po HH o Oo o o~ @) — — o — 8] i = QQ > ~ o E co + © A © OT i [00] [09] — [00] [o0] Q I I (} * ~N tn o Ie) ~ i) re o N Pe~ a x . . . . . . . . ] fi] >a NS [a¥} o o — N o o o o o — or hari ARI 3 Toro A [=] U+H 0 3 * 2 023 =
HH o — oN — le) — Qu — = — N ™ [s] AH PQ 0 Oo 19] T 1 uv N oO HS. 5 EE o tlelelelelelala|al, a B%Z0 0) O a} i — — — — — —t — I 5 8h 5 — 0) o a= 1 nN
Q > H © >on A © -— © 0,1
A BE ~ £923
H o o o o o — o ~ — a Hag % = > 0g A 0) Sg = © —
H eg Lm ~~ — — — o ® 2 —~ © | © 0) x o o o ™ o ™ Tel © 0 2 I go] * . . . . . . . . | [6] =. wn ~ oO [aF] (@] [@] — Oo [@] [@) o i aos HM oT a \% Vv \% 0 S = ~
TT © oO 1 ~ ow fo sd TO Nem
Q, [ORES] QZ 5 | 58 2g
H ) I foe) Xe} o 0 fo) oO = = = -— .0 9g 0H Eau -- © oH 5 > 57 fon l
I) H — 4 go! T 0 J WH as 38d og l) o o o o o o le) [@) © © © Mo = o 5 ~~ — — of — — pa £8 40g oO = co v & a > 5 N
I ZL 5585 n 9 20 9a . R . : [=I - : . : : M : © T 0 0 x=
K * Aq + Kg - [=u m3 m + ot ~| gag —~ gs 3 AA —_ — * ~~" | gO wn Un
TT =| © io] TT ~|T © oo ~ — £ no ~ 5 ce celcolen|eflol|ex] S| SaS5885 5 SZ |33 133x323] (Lov o| 5 oO OQ 59 | Q9loxloN|om|0E]|QE c 0 aPlaglaglar an 2g] S IS 5 . £ £ £ EEE | 8 —Ho|Ho O vs
O,|0o|06!p0 8) On| Hr] HN x x
OZI10& 04 Ln OU un © H — HH — y oxox ~— ~~ ~— ~ se EY * — x x x xX
AMENDED SHEET
Experiment 3 (HT-29 metastatic models)
A segment (2 mm?) of HT-29 cells (human colon cancer) was implanted into the vermiform appendix of 100NCr nu/nu female mice (5 to 6 weeks old, 10 animals per group).
Since the lymph node metastasis was observed on the 49th day after the implantation of tumor, a test compound (Compound A; the compound obtained in Preparation 1 as mentioned below, and Irinotechan (CPT-11l)) was dissolved in a physiological saline solution, and each amount as indicated in Table 3 as mentioned below was administered intravenously to the mice on the 51st, 55th, 58th, and 63rd day after the implantation of tumor. On the other hand, in the control group (untreated with test compound), only a physiclogical saline solution was administered. The presence or absence of the metastasis of each organ was checked on the 84th day after the implantation of tumor.
The results are shown in the following Table 3.
c — — . “nal x Sle ° I ot 2 0 on o o — p wm Vv | Vv = 0 5% § Ew o
ZH 0 oN ™ [oe] [=] ~ cE 0 © or [9 > x o o o x * . . . I Q go 4 ox ou — — — — - 0 un 0 4] £2 5 2 +" I=] PN
OD | «x o 0
H = oN | H — — O o [eo] = o, o =] + I] ge ?
N — — — o . o—- ~ | o ~ H > * - - L) ! © PN] on a o | o o 2 aq c o fing 3 [§]
UA x a. 0 =) o o o ™ 2 lire! o [SIR ~ a > 8
Ke) ££ o—~ x o o o I] ™ x B . . ] pe] Bo
Iv [=F] — — [= « oT 0 © © [TI — 5 4H Ry
Q or
S a |. ~- 23
Et ~
HH o o — — po A = > 0
QQ [LL =]
H 0g —t —t 2 — ©
Q * o o o IE © ho] x . . 1 0 [=3EN [¢] [oW) o o — 5a 22 = v v To ©o oO
Ko a To a, uv 9 x [<3
E, =! o ~ @ [o2} —H > [o] a = ol “9 [ST] E = 0 oH ’ ri So 9 : £P Zo
I) pe n 0, + “og o o o o ag © © MN 0.5 — | — — $8 Aw co (CR a »
Z = = © + on O 12] n £0
Sn -— 38.32 oT ™ Ev] Blan EN Ln fo} TO Ov fo} = = 0 3 CMe MoS a Sup HA o 3 [3 iv Oo O 5 2. 218. 82 F| ¢ © £ (gE “aol § "
OO ol0C ol F—
OO <0 njH ~— .e x x ~ «x x x x * x Xx
Experiment 4 (H460 metastatic models)
A segment (2 mm’) of H460 cells (human lung cancer) , was implanted into the left lung of 100NCr nu/nu female mice (5 to 6 weeks old, 10 animals per group). Since the metastasis was observed on the 14th day after the implantation of tumor in another control group, a test compound (Compound A; the compound obtained in Preparation 1 as mentioned below, Compound B; the compound obtained in
Preparation 4 as mentioned below, and Irinotechan (CPT-11)) was dissolved in a physiological saline solution, and each amount as indicated in Table 4 as mentioned below was administered intravenously to the mice on the 14th, 18th, 22nd and 26th day after the implantation of tumor. On the other hand, in the control group (untreated with test compound), only a physiological saline solution was administered. The presence or absence of the metastasis of each organ was checked on the 36th day after the implantation of tumor. The results are shown in the following Table 4.
Iu] wn @] — £ x — Sy oN Xe} Xe) oN ~N [e] [io] > wy Hon © oN o (@) o (@) (@) o x < o 3 on . . . . . . . . Q Fu} 2 Ww [@] (@] Oo @) o o [@] oO Q © iV = £
ACI @ (C) aw < << oO © © 14 Re)
EE» z 22 zg 2 — ™ — ~ ~ — — ~ N ie oi
I] > Ee f= 5h — Halle o Or. << [ee] Sl Si 5 ~ 0 on = * wn [Ts] in [@) Oo Te} Oo Te} + S100 + . . . . . . . . | = vox 0. © © o — oO — © 3 3433 o 0, > ~ c 0 £ co 3 + © A iS] - OT x eo Lg — o ~ o A — oO — o ™~ io [2 J st 0 ood £ SEE
S Tea © 403 n Fale 0, — =
I A EO Sle ele] = | 5 PQ [eT — - — - 2 2L4
H on ~ 1 ~ : 5 Tl = -r [0] So + + xX Pa o * o 0 oH — ) (@) o o o o o o o o o — 1 nN
Q = H > Oy A © IN 0
Et i HoT © Q +o oO E -A x — To} —t To) To} — — 0 © S © — 9 x o o o o o o o o : H 245% 0 Au o o o o o o o o oS Pre a Vv Vv iY Y 0 ra: fe — Mo [) ~ -
Q. T O RES
E, * ™ =a © No 0 — — he! s — ~ — ~ oN — o ~ lt 8x 25 = > 0 qo & on E°8
AO A5 > " BT 5 oR ~ 1+] 0 — 0 J 2D Og
Q 4 = o Oo Oo a} oO o o oO oO LI. 2 pT oO . — — — — i — — i ™ © 5 Ho in] 0 gp O = jo 0 £ > 5 nN
I = 5 5 ga 0 Op @ n Op AQ : « * : Son I : : : » > © 0 om : : : : . : —_ —_ Q : « ale <i |m: || = Em EOD om —_ — —~ fn iv] pv — gE nnn ~ 0 ColEo|22 20 8alET ol ol] o| 2.8885 3 SX|I52| 325253053 00|leo]| H =e aad ° oxo on|oN|ol|0oploEloE] 2 aac ag an an Qel ES I= © EEE = EE|EE|E |do|do]| § _— 0 Oo] 0 s| 0 0 Own|H<| Ho 3
ODQIOJQIOJZ|OD|O|O HH =H — x ox - —_ ~~ ~~ ~ ™~N ERI EI ~~ * ¥ * Xx
AMENDED SHEET
PREPARATIONS
Preparation 1
Preparation of CM-dextran-7-ethyl-10-[3'-(glycyl-glycyl- glycylamino)propyloxy]- (20S) -camptothecin: 0
CM-Dextran-(Gly)3;-NH-(CH5)3-O AN N | o
NT So
HsC> OH (CM-Dextran means carboxymethyldextran, hereinafter, the same) (1) 10-(3'-Aminopropyloxy)-7-ethyl-(20S)~camptothecin hydrochloride (500 mg) was dissolved in acetonitrile (25 ml), and thereto were successively added t-butoxycarbonyl glycyl—-glycyl-glycine (345 mg), N-methylmorpholine (121 mg),
N-hydroxybenzotriazole (161 mg) and l-(3-dimethylamino- propyl) -3-ethylcarbodiimide hydrochloride (228 mg), and the mixture was stirred overnight. The precipitated product was collected by filtration, purified by silica gel column chromatography to give pale yellow foamy powder, which was recrystallized from n-propanol to give 7-ethyl-10-[3'-(t- butoxycarbonyl-glycyl-glycyl-glycylamino)propyloxyl- (20S) - camptothecin (663 mg) as colorless crystals.
M.p.: 157-159°C. (2) 7-Ethyl-10-[3'- (t-butoxycarbonyl-glycyl-glycyl- glycylamino)propyloxy]-{20S)-camptothecin (3.86 g) was emulsified in purified water (64 ml), and thereto was added 6N aqueous hydrochloric acid solution (32 ml), and the mixture was reacted at room temperature under stirring for 2 hours. The solvent was concentrated, and thereto was
S) added n-propanol to precipitate powdery product. The resulting powdery product was collected by filtration, and recrystallized from aqueous n-propanol to give 7-ethyl-10- [3'-(glycyl-glycyl-glycylamino)propyloxyl- (20S) - camptothecin hydrochloride (2.56 g) as yellow crystals. (3) CM-Dextran sodium salt (CM-degree = 0.44, 50 g) was dissolved in water (2.5 liters), and the pH value thereof was adjusted to pH 5.0 with 0.2N aqueous hydrochloric acid solution under stirring at 15°C, and thereto was added 7- ethyl-10-[3'-(glycyl-glycyl-glycylamino)propyloxyl- (20S) - camptothecin hydrochloride (4.01 g). To the mixture was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (50 g), during which the pH value of the reaction solution was kept at 5.0-5.5 with 0.2N hydrochloric acid. The mixture was reacted at 15°C under stirred for one hour, and diluted to the total volume of 10 liters with purified water. While the pH value was kept at over pH 4.0, the low molecule fractions were removed by using an ultrafiltration module (ACP-1010, manufactured by
Asahi Kasei Industries, Ltd.), and the pH value thereof was adjusted to pH 8 with 0.1N aqueous sodium hydroxide solution, and then subjected to ion-exchange resin MSC-1 (Na-type, manufactured by Dowex). The fractions containing the desired compounds are concentrated, and filtered through a filter (0.45 pum). The resultant was mixed with ethanol (10 liters) with stirring, and thereto was added dropwise 3M brine (40 ml) under stirring. The resulting precipitates were collected by filtration, and dissolved in purified water (21 liters). The pH value of the solution was adjusted to pH 4.0 with 0.2N aqueous hydrochloric acid solution, and subjected again to ultrafiltration during which the pH value was kept at pH 4.0. The solvent was concentrated to the total volume of 1.5 liter, and filtered through a filter (0.45 um). The resultant was mixed with ethanol (9 liters), and thereto was added dropwise 3M brine (35 ml) under stirring. The resulting precipitates were collected by filtration, and washed successively with ethanol and acetone, concentrated under reduced pressure to give the desired compound (54.9 g) as pale yellow powder.
The content as 10-(3'-aminopropyloxy)-7-ethyl- (20S) - camptothecin hydrochloride was confirmed as 4.2 % by absorption at 367.5 nm. According to the analysis by GPC (Gel Permeation Chromatograph), the average molecular weight of the desired product was 121 kDa, and the degree of distribution (Mw/Mn) was 1.47.
Preparation 2
Preparation of CM-dextran-13-[(2'R,3'S)-3'-N-tert- butoxycarbonyl-3'-phenyl-2'-0-L-phenylalanyl-glycyl- isoserinyl]-10-deacyl-baccatin III:
HO, O OH
NH-Boc 2
R Otine-
OR C) 0
CM-Dextran-Phe-Gly-O O OH i AcO
BzO (Bz is benzoyl group, hereinafter, the same)
CM-Dextran (2008 mg, CM-degree: 0.47, the average molecular weight: 170 kDa) was dissolved with stirring in purified water (90 ml), and thereto were added 13- [(2'R,3'S)-3'-N-tert-butoxycarbonyl-3'-phenyl-2'-0-L- phenylalanyl-glycyl-isoserinyl]}-10-deacyl-baccatin III mesylate (119 mg) and dimethylformamide (90 ml), and the mixture was stirred so as to dissolve. To the mixture was added with stirring 2-ethoxy-1(2H)-quinolinecarboxylic acid (4.0 g), and the mixture was stirred at room temperature overnight. To the reaction solution was added ethanol (720 ml) with stirring, and thereto was further added dropwise 3M brine (1.8 ml) under stirring. The precipitates were collected by centrifugation, and dissolved in water (200 ml), and the pH value of the solution was adjusted to pH 7 with 0.2N agueous sodium hydroxide solution. The solution was poured into ethanol (800 ml) with stirring, and thereto was added dropwise 3M brine (4 ml) with stirring... The resulting precipitates were collected by centrifugation, and purified in the same manner as in Preparation 1-(3) to give the desired compound (600 mg) as white powder.
The content of the active substance: 2.4 % (UV method, (A = 276 nm))
Preparation 3
Preparation of CM-dextran-2'-O-phenylalanyl-glycyl-taxol:
AcO O OH
NH-Bz 2 Olin
CM-Dextran-Phe-Gly-O O OH 7 AO
B20
CM-Dextran (1.294g, CM-degree: 0.47, the average molecular weight: 170 kDa) was dissolved with stirring in purified water (70 ml), and thereto were added 2'-O-phenyl- alanyl-glycyltaxol mesylate (77 mg) and dimethylformamide (70 ml), and the mixture was further stirred so as to dissolve. 2-Ethoxy-1(2H)-quinolinecarboxylic acid (2.59 q) was added to the mixture under stirring, and the mixture was reacted with stirring overnight. The reaction solution was added to ethanol (700 ml) under stirring, and thereto was added dropwise 3M brine (1.4 ml) under stirring. The precipitates were collected by centrifugation, and dissolved in water (240 ml), and mixed with ethanol (1200 ml) under stirring. 3M Brine (4.8 ml) was added drowpise to the mixture under stirring for precipitation. In the same manner, the precipitation was further repeated three times to give the desired product (746 mg) as white powder.
The content of the active substance: 4.8 2 (UV method (A = 273 nm) )
Preparation 4
Preparation of carboxymethyldextran-polyalcohol-(1S,9S)-1- (glycyl-glycyl-L-phenylalanyl-glycylamino)-9-ethyl-5- fluoro-2, 3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de] - pyrano([3',4':6,7]indolizino(l, 2-blJquinoline-10,13 (9H, 15H) - dicne: (1) Preparation of (1S,9S)-1-(t-butoxycarbonyl-glycyl- glycyl-L-phenylalanyl-glycylamino)-9~ethyl-5-fluoro-2, 3- dihydro-9-hydroxy-4-methyl~1H, 12H-benzo [de] pyrano- [3',4':6,7]indolizino(1,2-blgquinoline-10,13 (9H, 15H) -dione:
Boc-Gly-Gly-Phe-Gly dn = =~
F N - @)
HsCY OH
To a solution of (13,98)-l-amino-9-ethyl-5-fluoroc-2, 3- dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de] pyrano- [3',4':6,7]indolizino{l,2-blquinoline-10,13 (9H, 15H) ~dione nydrochloride (167 mg; 0.354 mmol), t-butoxycarbonyl-
AMENDED SHEET glycyl-glycyl-L-phenylalanyl~glycine (463 mg; 1.06 mmol) and l-hydroxybenzotriazole monohydrate (HOBT) (143 mg; 1.06 mmol) in dimethylformamide (DMF) (10ml) were added 1- (3- dimethylaminopropyl)-3-ethylcarbodimimide (EDC) hydrochloride (270 mg; 1.42 mmol), triethylamine (148 nl; 1.06 mmol) and 4-dimethylaminopyridine (DMAP) (5 mg; 0.04 mmol). The reaction mixture was stirred at room temperature for 15 hours, and the solvent was concentrated under reduced pressure. The residue was dissolved in chloroform, and the mixture was washed, dried, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; chloroform : methanol = 50:1 to 10:1) to give the title compound (228 mg, yield: 75 8) as pale yellow solid.
IR (Nujol); 3290, 1710, 1655 cm’
ESI-MS; 854 (M+H) (2) Preparation of (1S,9S)~-1-(glycyl-glycyl-L-phenyl- alanyl-glycylamino)-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy- 4-methyl-1H, 12H-benzo[de]lpyrano([3',4':6,7]indolizino[1,2- bigquinoline-10,13(9H, 15H) -diocne:
Gly-Gly-Phe-Gly de
Me SAN No - HCI
F NTT ONC
HCY “OH
AMENDED SHEET
To a solution of (1S,9S)-1-(t-butoxycarbonyl-glycyl- glycyl-L-phenylalanyl-glycylamino)-9-ethyl-5-fluoro-2, 3- dihydro-9-hydroxy-4-methyl-1H, 12H-benzo[delpyrano- [3',4':6,7]indolizino(1l,2-blquinoline-10,13 (9H, 15H) -dione (220 mg; 0.258 mmol) in dioxane (4 ml) was added 4N hydrogen chloride solution in dioxane (6 ml) under stirring in an lce bath. The mixture was stirred at room temperature for 16 hours. Diethyl ether (30 ml) was added to the reaction mixture, and the mixture was stirred at room temperature for one hour. The precipitates were collected by filtration, and dried to give the title compound (176 mg, yield; 86 %) as yellow powder.
IR (Nujol); 3250, 1745, 1660, 1605, 1535 cm™
ESI-MS; 754 (M+H) (3) Preparation of dextran polyalcohol (PA-Dextran):
Acetic buffer (0.1 M, pH 5.5, 1000 ml) was put into a three-neck round bottom flask (capacity; 3 liters).
Dextran T-500® (10.0 g, manufactured by Amersham Pharmacia
Biotech AB) was added in small portions to the buffer over a period of 30 minutes at room temperature. The mixture was stirred for about 30 minutes until the solution became clear, and then, the mixture was cooled at 5°C (inner temperature) in a bath.
Separately, to a flask (capacity; 1 liter) were added sodium periodate (33.0 g) and water (1000 ml), and the
AMENDED SHEET mixture was stirred at room temperature, and then cooled at 5°cC.
To the above dextran solution was added with stirring the above sodium periodate solution at 5°C, and the mixture was ketp at 5°C for 5 days in a dark place. The excess sodium periodate was removed by adding ethylene glycol (10 ml), and the mixture was further stirred at 5°C for 2 hours.
The reaction mixture was cooled to 3°C, and thereto was added 8M aqueous sodium hydroxide solution during which the reaction temperature was kept below 6°C (the pH value of the reaction mixture became over pH 9). To the reaction mixture was added sodium borohydride (14 g¢g) in small portions with stirring, and the mixture was stirred at 5°C overnight. In order to remove the excess sodium borohydride, the pH value of the reaction mixture was adjusted to below PH 5.5 by adding acetic acid thereto at 3 to 6°C, and the mixture was further stirred for 2 hours.
The pH value of the reaction mixture was adjusted to about pH 7.8 with 8M aqueous sodium hydroxide solution. The mixture was subjected to dialysis against water (Spectora®/Por 3 membrane, Molecule weight cutoff <3500), and lyophilized to give dextran polyalcohol (8.34 g) as amorphous powder. (4) Preparation of carboxymethyldextran polyalcohol (CM-
PA-Dextran):
Water (155 ml) was put into a three-neck round bottom flask (capacity; 500 ml), and thereto was added with stirring dextran polyalcohol (5.18 g) at room temperature over a period of 10 minutes. The mixture was stirred for about 10 to 30 minutes until the mixture became clear, and then sodium hydroxide (pellet, 97.0 %, 21.8 g) was added to the dextran polyalcohol solution in small portions under stirring, during which the inner temperature was kept at 30 to 40°C in an ice bath. The reaction flask was put in a bath, and the mixture was stirred at 30°C. Chloroacetic acid (31.1 g) was added with stirring in small portions into the reaction mixture at 30 to 40°C. After the addition, the mixture was further stirred at 30°C in a bath for 20 hours. The reaction mixture was cooled in an ice bath, and the mixture was neutralized by adding thereto acetic acid under stirring (i.e., the pH value was adjusted to below pH 9).
Water (160 ml) was added to the mixture, and the mixture was subjected to dialysis against water {(Spectora®/Por 3 membrane, Molecule weight cutoff <3500), and lyophilized to give carboxymethydextran polyalcohol (6.53 g) as amorphous powder. (5) Preparation of carboxymethyldextran-polyalcohol- (18,98) -1- (glycyl-glycyl-L-phenylalanyl-glycylamino) -9- ethyl-5-fluoro-2, 3-dihydro~9-hydroxy-4-methyl-1H, 12H~ benzo([delpyrano(3',4':6,7]indolizino{1l,2-blquincline- 10,13 (9H, 15H) -dione:
Water (40 ml) was put into a round bottom flask (capacity; 100 ml), and thereto was added carboxymethyldextran polyalcohol (1.0g) at room temperature with stirring over a period of 5 minutes. The mixture was stirred about 30 minutes until the mixture became clear. A solution of (1S,9S)-1-(glycyl-glycyl-L-phenylalanyl- glycylamino) -9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4- methyl-1H, 12H-benzo{delpyrano(3',4':6,7]lindolizino[1l, 2~- blquinoline-10,13 (9H, 15H) ~dione in dimethylformamide (100 mg/10 ml) was added with stirring to the mixture, and further added thereto dimethylformamide (15 ml), and the mixture was stirred for 10 minutes. To the mixture was added dropwise with stirring a solution of 2-ethoxy-—-1- ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) in dimethyl- formamide (1.0 g/10 ml) at room temperature, and the mixture was further stirred for 18 hours. The reaction mixture was subjected to dialysis against water (Spectora®/Por 3 membrane, Molecule weight cutoff <3500), and further purified by cation exchange column (BioRad AG®
MP-50 column, Na-type, 30 ml). The main fraction was subjected to dialysis (Spectora®/Por 3 membrane, Molecule weight cutoff <«3500), and lyophilized to give a crude product, which was pulverized with acetone, collected by
AMENDED SHEET filtration, and dried to give the desired product (904 mg) . as pale yellow powder.
The pharmaceutical composition of the present invention may highly accumulate at the site such as lymph node or the liver to which cancers may spread, and suppressively act on the growth of tumor cells without affecting on the normal cells, and hence, the pharmaceutical composition of the present invention is useful in the inhibition of metastasis, particularly in the inhibition of lymph node metastasis or liver metastasis, or prevention of reoccurrence of a malignant tumor.
In addition, the present pharmaceutical composition may exhibit its effects not only before the onset of : metastasis but also after the onset of metastasis.
Therefore, the present pharmaceutical composition is also useful in the inhibition of metastasis or prevention of reoccurrence of a malignant tumor after topical therapy (e.g., surgery, radiation therapy, thermotherapy, cryotherapy, laser burning therapy, etc.).
Claims (9)
1. A pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different, or a salt thereof.
2. The pharmaceutical composition according to claim 1, wherein the active substance having an anti-tumor activity is a camptothecin derivative of the formula (I): RY 0 = ~ N Oo X'—Ak—0—— | | (1) HCY “OH wherein R! is a substituted or unsubstituted lower alkyl group, X! is a group of the formula: -NHR® (R? is a hydrogen atom or a lower alkyl group) and Alk is a straight chain or branched chain C,. alkylene group having optionally an oxygen atom in the chain thereof, or a compound of the formula (II):
R® R? eo} ] _ | (in R s N - 6) R HCY “OH wherein two groups of R? to R® being adjacent each other combine to form a lower alkylene group, and one of the carbon atoms of said lower alkylene group is substituted by an amino group, and the remaining three groups of R? to R® are a hydrogen atom, a lower alkyl group or a halogen atom.
3. The pharmaceutical composition according to claim 1 or claim 2, wherein the polysaccharide having a carboxyl group is a carboxy-C,., alkyldextran or a carboxy-C,, alkyldextran polyalcohol.
4. The pharmaceutical composition according to claim 1 or claim 2, wherein the polysaccharide having a carboxyl group is a carboxy-C,, alkyldextran.
5. The pharmaceutical composition according to any one of claims 1, 2, 3 and 4, wherein the peptide is a member selected from the group consisting of glycyl-glycyl-L- or D-phenylalanyl-glycine, glycyl-glycine, glycyl-glycyl- glycine, glycyl-glycyl-glycyl-glycine, glycyl-glycyl- glycyl-glycyl~-glycine, L- or D-phenylalanyl-glycine, L- or D-tyrosyl-glycine, L- or D-leucyl-glycine, L- or D- phenylalanyl-citrulline and L- or D-valyl-citrulline.
6. The pharmaceutical composition according to claim 1,
wherein the polysaccharide having a carboxyl group is a carboxymethylated dextran, the active substance having an anti-tumor activity is 10-(3’-aminopropyloxy)-7-ethyl- (208) —~camptothecin, and the peptide is glycyl-glycyl- glycine.
7. The pharmaceutical composition according to claim 1, wherein the polysaccharide having a carboxyl group is a carboxy-C,., alkyldextran polyalcohol, the active substance having an anti-tumor activity is (1S, 9S)-l-amino-9-ethyl- 5-fluoro-2, 3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de] - pyrano(3’,4’:6,7]indolizino(l,2-blgquinoline-10,13 (9H, 15H) - dione, and the peptide is glycyl-glycyl-L- or D-phenyl- alanyl-glycine.
8. The pharmaceutical composition according to any one of claims 1 to 7, which is a pharmaceutical composition for inhibiting the metastasis of a malignant tumor.
9. The pharmaceutical composition according to any one of claims 1 to 7, which is a pharmaceutical composition for preventing the recurrence of a malignant tumor. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001249717 | 2001-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200400917B true ZA200400917B (en) | 2004-08-25 |
Family
ID=19078678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200400917A ZA200400917B (en) | 2001-08-21 | 2004-02-04 | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1418947A1 (en) |
KR (1) | KR20040027972A (en) |
CN (1) | CN100372570C (en) |
AR (1) | AR035137A1 (en) |
AU (1) | AU2002328093B2 (en) |
BR (1) | BR0212036A (en) |
CA (1) | CA2457056C (en) |
HU (1) | HUP0401351A3 (en) |
IL (1) | IL160148A0 (en) |
MX (1) | MXPA04001599A (en) |
NO (1) | NO20041194L (en) |
NZ (1) | NZ530947A (en) |
PL (1) | PL368319A1 (en) |
RU (1) | RU2275913C2 (en) |
TW (1) | TWI313609B (en) |
UA (1) | UA75450C2 (en) |
WO (1) | WO2003015826A1 (en) |
ZA (1) | ZA200400917B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200306314A (en) * | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
FR2914305B1 (en) * | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS |
DK2313487T3 (en) | 2008-07-16 | 2018-06-18 | Childrens Medical Center | ORGANIZING DEVICE WITH MICRO-CHANNELS AND METHODS OF APPLICATION |
WO2012166903A1 (en) | 2011-06-02 | 2012-12-06 | President And Fellows Of Harvard College | Methods and uses for ex vivo tissue culture systems |
PL221351B1 (en) | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Method for obtaining polysaccharide nanoparticles |
DK2907824T3 (en) | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
ES2782248T3 (en) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate produced by binding through a linker having a hydrophilic structure |
DK3466976T3 (en) | 2014-01-31 | 2021-12-13 | Daiichi Sankyo Co Ltd | ANTI-HER2-ANTIBODY-MEDICINE CONJUGATE |
EP3292146A1 (en) | 2015-05-04 | 2018-03-14 | Pfizer Inc | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
AU2016286898B2 (en) | 2015-06-29 | 2022-12-08 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
WO2018110515A1 (en) | 2016-12-12 | 2018-06-21 | 第一三共株式会社 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
KR102537651B1 (en) | 2017-01-17 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | Anti-GPR20 Antibodies and Anti-GPR20 Antibody-Drug Conjugates |
TWI794230B (en) | 2017-05-15 | 2023-03-01 | 日商第一三共股份有限公司 | Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof |
CA3073924C (en) | 2017-08-31 | 2023-10-17 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
BR112020003466B1 (en) | 2017-08-31 | 2023-12-12 | Daiichi Sankyo Company, Limited | COMPOST PRODUCTION METHODS, AND, COMPOST |
JP2021524740A (en) | 2018-05-18 | 2021-09-16 | グリコトープ ゲーエムベーハー | Anti-MUC1 antibody |
CN109481691A (en) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | Gemcitabine-carboxymethyl polysaccharide conjugate, preparation method and its usage |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2134348C (en) * | 1993-02-26 | 2007-01-02 | Hideo Nogusa | Polysaccharide derivatives and drug carriers |
SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
EP0895784B1 (en) * | 1996-04-15 | 2005-11-23 | Asahi Kasei Kabushiki Kaisha | Drug complexes comprising taxane compounds or steroids |
TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
CN1058038C (en) * | 1996-12-31 | 2000-11-01 | 中国科学院感光化学研究所 | Low contract photo-solidification cladding material, its prepn. method and use |
CN1250293C (en) * | 1998-05-22 | 2006-04-12 | 第一制药株式会社 | Drug composites |
-
2002
- 2002-08-14 TW TW091118260A patent/TWI313609B/en not_active IP Right Cessation
- 2002-08-15 AR ARP020103077A patent/AR035137A1/en unknown
- 2002-08-16 NZ NZ530947A patent/NZ530947A/en not_active IP Right Cessation
- 2002-08-16 EP EP02762786A patent/EP1418947A1/en not_active Withdrawn
- 2002-08-16 AU AU2002328093A patent/AU2002328093B2/en not_active Ceased
- 2002-08-16 CN CNB028163176A patent/CN100372570C/en not_active Expired - Fee Related
- 2002-08-16 KR KR10-2004-7002566A patent/KR20040027972A/en not_active Application Discontinuation
- 2002-08-16 CA CA002457056A patent/CA2457056C/en not_active Expired - Fee Related
- 2002-08-16 BR BR0212036-4A patent/BR0212036A/en not_active IP Right Cessation
- 2002-08-16 WO PCT/JP2002/008309 patent/WO2003015826A1/en active IP Right Grant
- 2002-08-16 HU HU0401351A patent/HUP0401351A3/en unknown
- 2002-08-16 PL PL02368319A patent/PL368319A1/en not_active Application Discontinuation
- 2002-08-16 RU RU2004108141/15A patent/RU2275913C2/en not_active IP Right Cessation
- 2002-08-16 MX MXPA04001599A patent/MXPA04001599A/en unknown
- 2002-08-16 UA UA2004032071A patent/UA75450C2/en unknown
- 2002-08-16 IL IL16014802A patent/IL160148A0/en unknown
-
2004
- 2004-02-04 ZA ZA200400917A patent/ZA200400917B/en unknown
- 2004-03-19 NO NO20041194A patent/NO20041194L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2457056C (en) | 2008-07-22 |
BR0212036A (en) | 2004-08-17 |
CN1545423A (en) | 2004-11-10 |
NO20041194L (en) | 2004-03-19 |
IL160148A0 (en) | 2004-07-25 |
TWI313609B (en) | 2009-08-21 |
KR20040027972A (en) | 2004-04-01 |
EP1418947A1 (en) | 2004-05-19 |
WO2003015826A1 (en) | 2003-02-27 |
HUP0401351A3 (en) | 2011-02-28 |
RU2004108141A (en) | 2005-04-20 |
HUP0401351A2 (en) | 2004-12-28 |
CA2457056A1 (en) | 2003-02-27 |
RU2275913C2 (en) | 2006-05-10 |
AU2002328093B2 (en) | 2005-05-05 |
UA75450C2 (en) | 2006-04-17 |
PL368319A1 (en) | 2005-03-21 |
CN100372570C (en) | 2008-03-05 |
MXPA04001599A (en) | 2004-07-08 |
AR035137A1 (en) | 2004-04-14 |
NZ530947A (en) | 2006-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200400917B (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor. | |
EP0916348B1 (en) | alkyldextran-polyalcohol drug complexes | |
ES2198421T3 (en) | DERIVATIVES OF CAMPTOTECHINE UNITED TO POLYMERS. | |
ES2229355T3 (en) | PROCEDURE FOR THE MANUFACTURE OF MEDICINAL COMPLEXES. | |
AU2002328093A1 (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor | |
AU2015306574B2 (en) | Specifically activated micromolecular target coupling body in tumor microenvironment and use thereof | |
JPS6259715B2 (en) | ||
JP6957629B2 (en) | Non-linear self-destructive linker and its conjugate | |
KR20160064726A (en) | Conjugate of Cell Penetrating Peptides-Anti-cancer Agent and Composition Comprising the Same | |
EP2692777B1 (en) | Pharmaceutical composition containing block copolymer comprising boronic acid compound | |
JPH1192405A (en) | Medicinal complex | |
JP2014196304A (en) | Compound | |
US20060052288A1 (en) | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | |
WO1988008715A1 (en) | Method of tumor inhibition in warm-blooded animals | |
JPH1171280A (en) | Medicine composition | |
EP3071238B1 (en) | Conjugate comprising indole-3-carbinol for medical use | |
JP2003137818A (en) | Composition for metastasis control or recurrence prevention of carcinoma | |
CA3210473A1 (en) | Branched linkers for antibody-drug conjugates and methods of use thereof | |
KR100481434B1 (en) | Manufacturing method of drug complex |